Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept